Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5.8Revenue (TTM) $M9.2Net Margin (%)-175.8Altman Z-Score-19.2
Enterprise Value $M3.4EPS (TTM) $-9.3Operating Margin %-169.6Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-176.1Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %-45.1Quick Ratio2.5Cash flow > EarningsN
Price/Sales0.45-y EBITDA Growth Rate %-37.1Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow0.4y-y EBITDA Growth Rate %--ROA % (ttm)-98.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-132.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M2.4ROIC % (ttm)-364.3Gross Margin Increase y-yN

Gurus Latest Trades with ROSG

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ROSG is held by these investors:



ROSG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ROSG :

Quarterly/Annual Reports about ROSG:

    News about ROSG:

    Articles On GuruFocus.com
    Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
    Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

    More From Other Websites
    New Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary... Apr 27 2017
    Edited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT Mar 30 2017
    Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results Mar 30 2017
    Rosetta Genomics to Host 2016 Fourth Quarter and Year End Financial Results and Business Update... Mar 23 2017
    Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay Mar 20 2017
    Rosetta Genomics Announces 1-for-12 Reverse Stock Split Mar 16 2017
    Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible... Feb 23 2017
    Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth... Feb 08 2017
    Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs Feb 06 2017
    Rosetta Genomics Reports Third Quarter 2016 Financial Results Dec 20 2016
    Rosetta Genomics to Present at the 9th Annual LD Micro Main Event Dec 01 2016
    Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement... Nov 23 2016
    Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to... Nov 21 2016
    Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology Oct 27 2016
    Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer Oct 20 2016
    Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its... Oct 03 2016
    Rosetta Genomics Enters Distribution Agreement for RosettaGX Reveal™ in Israel with Rhenium Sep 29 2016
    Rosetta Genomics Reports 2016 Second Quarter Financial Results Sep 26 2016
    Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call... Sep 20 2016
    Data Validating the Utility of RosettaGX Reveal™ with Liquid-based Cytology Samples will be... Sep 14 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)